Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma

The present study analyzed the expression of the histone deacetylase (HDAC) 1, 2 and 3 in primary esophageal squamous cell carcinoma (ESCC) samples and how their levels correlate with clinicopathological parameters. ESCC patients (n=88) in the present study had received no previous treatment before undergoing surgical excision. The mRNA expression of HDAC1, -2 and -3 were detected by semi-quantified PCR in ESCC samples and distal normal samples. The relationship of HDAC1, -2 and -3 expression with clinicopathological parameters was analyzed by χ2 test. The correlation among these HDACs was analyzed by Pearson's correlation test. Compared with distal normal tissues, ESCC samples had higher expression of HDAC1, but not HDAC2 or HDAC3 (P<0.05). The expression of HDACs was different between Kazak and Han ethnicities. The expression of HDAC2 was correlated with invasion depth (P<0.05), but not with sex, age, metastasis, or the degree of tumor differentiation (P>0.05). There was no association between HDAC1 or HDAC3 and clinicopathological parameters (P>0.05). For the Kazak and Han ethnicities, HDAC1 expression was present in male patients, patients with well/moderate differentiated ESCC and T3 and T4 ESCC (P<0.01). HDAC1 in patients aged <60 was associated with ethnicity (P<0.05). HDAC2 expression was different in positive LN metastasis, well/moderate differentiation and T3 and T4 ESCC (P<0.01). HDAC3 expression in male patients, patients with negative LN metastasis and well/moderate differentiation ESCC was associated with ethnicity (P<0.05). Additionally, the expression levels of HDAC1, -2 and -3 did not correlate with each other. Thus, HDAC1 expression may be used as a risk factor for ESCC and HDAC2 levels may be used to predict invasion depth. The expression of HDAC1, -2 and -3 has ethnic differences.

[1]  Jianfei Shen,et al.  miR-30b-5p acts as a tumor suppressor microRNA in esophageal squamous cell carcinoma. , 2019, Journal of thoracic disease.

[2]  Q. Peng,et al.  Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma , 2018, Investigational New Drugs.

[3]  Miao Deng,et al.  Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[4]  Y. Takeda,et al.  Role of histone deacetylase 1 in distant metastasis of pancreatic ductal cancer , 2018, Cancer science.

[5]  J. Lagergren,et al.  Global time trends in the incidence of esophageal squamous cell carcinoma , 2018, Clinical epidemiology.

[6]  B. Groner,et al.  The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells , 2018, Archives of Toxicology.

[7]  Tuan Leng Tay,et al.  Histone Deacetylases 1 and 2 Regulate Microglia Function during Development, Homeostasis, and Neurodegeneration in a Context‐Dependent Manner , 2018, Immunity.

[8]  H. Kafil,et al.  Deregulated expression of HDAC3 in colorectal cancer and its clinical significance. , 2018, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[9]  M. Christmann,et al.  HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130 , 2018, Nature Communications.

[10]  Meng Li,et al.  Histone Deacetylase 1 Plays an Acetylation-Independent Role in Influenza A Virus Replication , 2017, Front. Immunol..

[11]  Minghui Zhang,et al.  Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5 , 2017, International journal of molecular medicine.

[12]  F. Tirone,et al.  HDAC1, HDAC4, and HDAC9 Bind to PC3/Tis21/Btg2 and Are Required for Its Inhibition of Cell Cycle Progression and Cyclin D1 Expression , 2017, Journal of cellular physiology.

[13]  Lianhua Liu,et al.  The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy , 2017, Oncotarget.

[14]  Elizabeth E. Hull,et al.  HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases , 2016, BioMed research international.

[15]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[16]  Meng Zhuo,et al.  Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer , 2016, Oncotarget.

[17]  Somy Yoon,et al.  HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases , 2016, Chonnam medical journal.

[18]  D. Harrison,et al.  The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer , 2015, Oncotarget.

[19]  E. Chiocca,et al.  Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy , 2015, Oncolytic virotherapy.

[20]  G. Sauter,et al.  HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. , 2015, Experimental and molecular pathology.

[21]  M. Boerries,et al.  Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine , 2015, Epigenetics.

[22]  Furhawn A. Shah,et al.  Impact of histone deacetylase 1 and metastasis-associated gene 1 expression in esophageal carcinogenesis , 2014, Oncology letters.

[23]  G. Sica,et al.  Class I HDACs Are Mediators of Smoke Carcinogen–Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer , 2014, Cancer Prevention Research.

[24]  Limei Liu,et al.  Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification. , 2013, Cancer letters.

[25]  Wei He,et al.  HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9. , 2013, Clinical and investigative medicine. Medecine clinique et experimentale.

[26]  J. Zhao,et al.  X-radiation inhibits histone deacetylase 1 and 2, upregulates Axin expression and induces apoptosis in non-small cell lung cancer , 2012, Radiation oncology.

[27]  I. Rahman,et al.  Role of histone deacetylase 2 in epigenetics and cellular senescence: implications in lung inflammaging and COPD. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[28]  Suk Woo Nam,et al.  HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins , 2012, Journal of cellular biochemistry.

[29]  V. Beral,et al.  Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy , 2011, Journal of the National Cancer Institute.

[30]  R. Langer,et al.  Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study , 2010, Journal of Clinical Pathology.

[31]  T. Shiozawa,et al.  Type‐specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E‐cadherin , 2010, International journal of cancer.

[32]  R. Langer,et al.  Histone Deacetylase (HDAC) 1 and 2 Expression and Chemotherapy in Gastric Cancer , 2010, Annals of Surgical Oncology.

[33]  S. Motoyama,et al.  Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung , 2010, Tumor Biology.

[34]  H. Matsubara,et al.  Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma. , 2009, Anticancer research.

[35]  P. Barnes Histone deacetylase-2 and airway disease , 2009, Therapeutic advances in respiratory disease.

[36]  D. Saur,et al.  HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA , 2009, Gut.

[37]  O. Witt,et al.  HDAC family: What are the cancer relevant targets? , 2009, Cancer letters.

[38]  W. Weichert,et al.  Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo , 2008, Clinical Cancer Research.

[39]  H. Matsubara,et al.  Role of histone deacetylase inhibitor in adenovirus-mediated p53 gene therapy in esophageal cancer. , 2008, Anticancer research.

[40]  Carsten Denkert,et al.  Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. , 2008, The Lancet. Oncology.

[41]  J. Davie,et al.  Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. , 2007, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[42]  E. Seto,et al.  Histone deacetylases and cancer , 2007, Oncogene.

[43]  Hiroko Yamashita,et al.  Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast* , 2005, Breast Cancer Research and Treatment.

[44]  M. Salto‐Tellez,et al.  Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 , 2005, Cell Death and Differentiation.

[45]  Y. Ikeda,et al.  Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. , 2003, Oncology reports.

[46]  Yuka Kanno,et al.  Interaction of Histone Acetylases and Deacetylases In Vivo , 2003, Molecular and Cellular Biology.

[47]  F. Bray,et al.  Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.

[48]  J. Qin,et al.  Both corepressor proteins SMRT and N‐CoR exist in large protein complexes containing HDAC3 , 2000, The EMBO journal.

[49]  S. Schreiber,et al.  A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p , 1996, Science.

[50]  N. Zhang,et al.  HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells. , 2017, Oncology letters.

[51]  V. Ganapathy,et al.  Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. , 2009, The Biochemical journal.